IDE397 (MAT2A inhibitor)

Ideaya Biosciences

IDE397 is an oral MAT2A inhibitor by Ideaya Biosciences (IDYA 0.00%↑) that is currently in phase 1/2 trials for solid tumors harboring methylthioadenosine phosphorylase (MTAP)-homozygous deletions (NCT04794699).

Some bio background on why people think this is a good target

Homozygous deletion of CDKN2A/B at the 9p21 chromosome is an early clonal event in tumorigenes…